MedImmune FluMist Sales Of $30 Mil. Expected; 50% Return Rate Possible
MedImmune expects to record about $30 mil. of sales-related revenue for the FluMist nasal flu vaccine during the 2003-2004 launch season
MedImmune expects to record about $30 mil. of sales-related revenue for the FluMist nasal flu vaccine during the 2003-2004 launch season